BioCryst Pharmaceuticals, Inc.
8.115USD
-0.6900 (-7.84%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 270.8M | 331.4M | 450.7M | 874.8M | 702.2M | 737.3M |
| Q1 | 49.9M | 68.8M | 92.8M | 145.5M | 156.4M | — |
| Q2 | 65.5M | 82.5M | 109.3M | 163.4M | 218.3M | — |
| Q3 | 75.8M | 86.7M | 117.1M | 159.4M | 165.5M | — |
| Q4 | 79.5M* | 93.4M* | 131.5M* | 406.6M* | 169.4M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.33 | -1.18 | -.430 | 1.21 | .745 | .940 |
| Q1 | -.400 | -.280 | -.170 | .000 | -2.98 | — |
| Q2 | -.320 | -.400 | -.060 | .020 | .300 | — |
| Q3 | -.230 | -.190 | -.070 | .060 | .115 | — |
| Q4 | -.385* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.321* |
| -.130* |
| 1.12* |
| .125 |
| — |